Exchange: NASDAQ·Updated 07:30 PM EST

IBBQ News

News
all
press releases
Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug
AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said.
Stocktwits
Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug
AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said.
Stocktwits
More News
The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said.
Stocktwits
The company recently met with the FDA and believes that the agency no longer considers the data from an early-to-mid-stage trial of its investigational gene therapy sufficient for approval.
Stocktwits
Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.
Stocktwits
The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease.
Stocktwits
Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.
barchart.com
A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.
Stocktwits

Advertisement|Remove ads.